Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab.
Anti-CD20-antibody
B-cell depletion
COVID-19
COVID-19, Coronavirus disease 2019
CoV-2-S-AB, SARS-CoV-2 S protein antibodies
Ct, Cycle threshold
LTOT, Long term oxygen therapy
Monoclonal antibody
PCR, polymerase chain reaction
Persistent COVID-19
SARS-CoV-2
SARS-CoV-2, Severe acute respiratory syndrome coronavirus type2
Sotrovimab
mABs, monoclonal antibodies
Journal
IDCases
ISSN: 2214-2509
Titre abrégé: IDCases
Pays: Netherlands
ID NLM: 101634540
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
04
2022
accepted:
04
06
2022
pubmed:
14
6
2022
medline:
14
6
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
Patients having undergone B-cell-depletion with anti-CD20-antibodies have a higher risk of mortality, delayed viral clearance and prolonged infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report two cases of patients with persistent coronavirus disease 2019 (COVID-19) in association with B-cell-depletion that were treated with the monoclonal antibody Sotrovimab. Both patients presented with chronic symptoms of COVID-19 such as dyspnea, fatigue, and chest pain. Nasopharyngeal swabs remained positive months after the initial infection with fluctuating cycle threshold (Ct) values around 30. Both patients received a single infusion with the monoclonal SARS-CoV-2 antibody Sotrovimab, which resulted in a rapid improvement of symptoms and inflammation markers as well as negative SARS-CoV-2 swabs. A follow-up after a month showed ongoing improvement of symptoms, persistent negative SARS-CoV-2 swabs, and positive serum antibodies. Infusion with the monoclonal SARS-CoV-2 antibody led to rapid improvement in two patients with persistent COVID-19 after B-cell depletion.
Sections du résumé
Background
UNASSIGNED
Patients having undergone B-cell-depletion with anti-CD20-antibodies have a higher risk of mortality, delayed viral clearance and prolonged infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report two cases of patients with persistent coronavirus disease 2019 (COVID-19) in association with B-cell-depletion that were treated with the monoclonal antibody Sotrovimab.
Case presentation
UNASSIGNED
Both patients presented with chronic symptoms of COVID-19 such as dyspnea, fatigue, and chest pain. Nasopharyngeal swabs remained positive months after the initial infection with fluctuating cycle threshold (Ct) values around 30. Both patients received a single infusion with the monoclonal SARS-CoV-2 antibody Sotrovimab, which resulted in a rapid improvement of symptoms and inflammation markers as well as negative SARS-CoV-2 swabs. A follow-up after a month showed ongoing improvement of symptoms, persistent negative SARS-CoV-2 swabs, and positive serum antibodies.
Conclusion
UNASSIGNED
Infusion with the monoclonal SARS-CoV-2 antibody led to rapid improvement in two patients with persistent COVID-19 after B-cell depletion.
Identifiants
pubmed: 35694274
doi: 10.1016/j.idcr.2022.e01528
pii: S2214-2509(22)00156-1
pmc: PMC9172259
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e01528Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
mSphere. 2020 Mar 18;5(2):
pubmed: 32188753
Br J Haematol. 2020 Jul;190(2):185-188
pubmed: 32557623
Blood. 2020 Nov 12;136(20):2290-2295
pubmed: 32959052
Rheumatol Int. 2020 Dec;40(12):2015-2021
pubmed: 32945944
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Acta Clin Belg. 2019 Aug;74(4):272-279
pubmed: 30253707
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Ann Rheum Dis. 2021 Jul;80(7):930-942
pubmed: 33504483
Front Immunol. 2021 Apr 21;12:613502
pubmed: 33968017
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Int J Infect Dis. 2021 Jun;107:247-250
pubmed: 33901654
BMJ Case Rep. 2021 Aug 3;14(8):
pubmed: 34344651
Int J Mol Sci. 2021 Oct 10;22(20):
pubmed: 34681595
Drugs. 2003;63(8):803-43
pubmed: 12662126
Respir Med Case Rep. 2021;34:101560
pubmed: 34868871
Am J Hematol. 2021 Aug 1;96(8):934-944
pubmed: 33909916
Leukemia. 2020 Jun;34(6):1637-1645
pubmed: 32332856
Clin Infect Dis. 2022 May 30;74(10):1786-1794
pubmed: 34383032
Viruses. 2021 Jun 23;13(7):
pubmed: 34201591